Seeking Alpha: Nobel Biocare Has Gotten Its Teeth Kicked In

How unpopular is Swiss dental device company Nobel Biocare (NBHGY.PK)? The stock was down 30% in 2012 and is down 75% over the past three years, but the stock still carries an overwhelming number of "Sell" recommendations. While Nobel has seen some significant negative developments in its core dental implants market, it's still worth asking whether this stock may not carry some value for risk-tolerant deep-value turnaround investors.

Please click below for more:
Nobel Biocare Has Gotten Its Teeth Kicked In

Seeking Alpha: Dentsply - A Great Stock, But Not A Great Price

Dental care has held up better than most analysts expected, and Dentsply's (XRAY) to decision to continue investing in the business during the worst of the downturn should put it in place to gain even more share. That said, the stock's relative outperformance has left it a little expensive when compared to the larger med-tech universe.

A Confusing Q4
Dentsply's financial press releases are never what you might call a vault of information, and this is a company where shareholders should definitely make a point of listening to the conference call or reading the transcript. That said, even with the supplementary information, this was a complicated quarter.

Please continue here:
Dentsply: A Great Stock, But Not A Great Price